Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide

American Journal of Hypertension

Volumn 17, Issue 3, 2004, Pages 252-259

  Chrysant, Steven G ^a,d   Weber, Michael A ^b   Wang, Antonia C ^c   Hinman, Donald J ^c  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b SUNY Downstate Medical Center   (United States)

^c DAIICHI SANKYO INC   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Combination therapy; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; OLMESARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; SODIUM CHLORIDE SYMPORTER INHIBITORS; SYSTOLE; TETRAZOLES; TREATMENT OUTCOME; UNITED STATES;

EID: 1442299290     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.11.003     Document Type: Article

References (38)

1. Burt V.L., Whelton P., Roccella E.J., Brown C., Cutler J.A., Higgins M., Horan M.J., Labarthe D. Prevalence of hypertension in the US adult population results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
2. Hyman D.J., Pavlik V.N. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 345:2001;479-486.
3. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L. Jr, Jones D.W., Materson B.J., Oparil S., Wright J.T. Jr, Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 Report. JAMA. 289:2003;2560-2572.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. Br Med J. 317:1998;703-713.
5. HOT Study Group, Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 351:1998;1755-1762.
6. Kusek J.W., Lee J.Y., Smith D.E., Milligan S., Faulkner M., Cornell C.E., Kopple J.D., Greene P.G. Effect of blood pressure control and antihypertensive drug regimen on quality of life the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 17:(Suppl 4):1996;40S-46S.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997.
8. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153.
9. Chrysant S.G. Vascular remodeling the role of angiotensin-converting enzyme inhibitors. Am Heart J. 135:1998;S21-S30.
10. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
11. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 338:1998;645-652.
12. Collaborative Study Group, Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
13. RENAAL Study Investigators, Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
14. Collaborative Study Group, Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
15. Valsartan Heart Failure Trial Investigators, Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675.
16. LIFE Study Group, Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 359:2002;995-1003.
17. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 25:(Suppl 1):2002;S85-S89.
18. Neutel J.M. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 87:(Suppl):2001;37C-43C.
19. Stumpe K.O., Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 16:(Suppl 2):2002;S24-S28.
20. Van Mieghem W. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension. J Hypertens. 19:(Suppl 2):2001;S152-S153. (Abstract).
21. Chrysant S.G., Marbury T., Robinson T.S. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens. 17:2003;425-432.
22. Oparil S., Williams D., Chrysant S.G., Marbury T.C., Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 3:2001;283-291. 318.
23. Schrijver G., Weinberger M.H. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther. 25:1979;33-42.
24. Pickkers P., Hughes A.D., Russel F.G., Thien T., Smits P. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension. 32:1998;1071-1076.
25. Chrysant S.G., Lisinopril-Hydrochlorothiazide Group. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination a large multicenter study. Arch Intern Med. 154:1994;737-743.
26. Chrysant S.G., Fagan T., Glazer R., Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 5:1996;17-24.
27. Chrysant S.G., Fox A.A., Stimpel M. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hypertens. 8:1995;418-421.
28. Chrysant S.G. Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension a multicenter study. J Clin Pharmacol. 37:1997;47-52.
29. Chrysant S.G. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med. 7:1998;370-376.
30. Hung H.M., Chi G.Y., Lipicky R.J. Testing for the existence of a desirable dose combination. Biometrics. 49:1993;85-94.
31. Kochar M., Guthrie R., Triscari J., Kassler-Taub K., Reeves R.A. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 12:1999;797-805.
32. Hansson L., Smith D.H., Reeves R., Lapuerta P. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med. 160:2000;1654-1658.
33. Estacio R.O., Schrier R.W. Antihypertensive therapy in type 2 diabetes implications of the Appropriate Blood pressure Control in Diabetes (ABCD) trial. Am J Cardiol. 82:(Suppl 9B):1998;9R-14R.
34. Neutel J.M., Smith D.H., Weber M.A. Low-dose combination therapy an important first-line treatment in the management of hypertension. Am J Hypertens. 14:2001;286-292.
35. Chrysant S.G., Womboldt D.G., Feliciano N., Zheng H. Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther Res. 59:1998;762-772.
36. Corvol P., Plouin P.F. Angiotensin II receptor blockers current status and future prospects. Drugs. 62:2002;53-64.
37. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 103:2001;904-912.
38. Moser M., Black H.R. The role of combination therapy in the treatment of hypertension. Am J Hypertens. 11:1998;73S-78S.